WO2004067569A8 - Molecules de liaison humaines d'internalisation dirigees contre cd72 - Google Patents

Molecules de liaison humaines d'internalisation dirigees contre cd72

Info

Publication number
WO2004067569A8
WO2004067569A8 PCT/EP2003/050004 EP0350004W WO2004067569A8 WO 2004067569 A8 WO2004067569 A8 WO 2004067569A8 EP 0350004 W EP0350004 W EP 0350004W WO 2004067569 A8 WO2004067569 A8 WO 2004067569A8
Authority
WO
WIPO (PCT)
Prior art keywords
internalising
human binding
binding molecules
molecules against
human
Prior art date
Application number
PCT/EP2003/050004
Other languages
English (en)
Other versions
WO2004067569A1 (fr
Inventor
Alexander Berthold Hend Bakker
Willem Egbert Marissen
Original Assignee
Crucell Holland Bv
Alexander Berthold Hend Bakker
Willem Egbert Marissen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv, Alexander Berthold Hend Bakker, Willem Egbert Marissen filed Critical Crucell Holland Bv
Priority to AU2003209753A priority Critical patent/AU2003209753A1/en
Priority to PCT/EP2003/050004 priority patent/WO2004067569A1/fr
Publication of WO2004067569A1 publication Critical patent/WO2004067569A1/fr
Publication of WO2004067569A8 publication Critical patent/WO2004067569A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des molécules de liaison humaines d'internalisation qui se lient spécifiquement à CD72, des molécules d'acides nucléiques codant ces molécules de liaison humaines d'internalisation, des compositions comportant ces molécules de liaison humaines d'internalisation et des procédés d'identification ou de production de ces molécules de liaison humaines d'internalisation. Dans un mode de réalisation préféré, l'invention se rapporte à des immunoconjugués comportant une molécule de liaison humaine d'internalisation qui se lie spécifiquement à CD72. Les molécules de liaison humaines d'internalisation et des immunoconjugués comprenant une molécule de liaison humaine d'internalisation peuvent être utilisés pour le diagnostic et le traitement de troubles associés aux lymphocytes B.
PCT/EP2003/050004 2003-01-27 2003-01-27 Molecules de liaison humaines d'internalisation dirigees contre cd72 WO2004067569A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003209753A AU2003209753A1 (en) 2003-01-27 2003-01-27 Internalising human binding molecules against cd72
PCT/EP2003/050004 WO2004067569A1 (fr) 2003-01-27 2003-01-27 Molecules de liaison humaines d'internalisation dirigees contre cd72

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2003/050004 WO2004067569A1 (fr) 2003-01-27 2003-01-27 Molecules de liaison humaines d'internalisation dirigees contre cd72

Publications (2)

Publication Number Publication Date
WO2004067569A1 WO2004067569A1 (fr) 2004-08-12
WO2004067569A8 true WO2004067569A8 (fr) 2005-03-17

Family

ID=32798703

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/050004 WO2004067569A1 (fr) 2003-01-27 2003-01-27 Molecules de liaison humaines d'internalisation dirigees contre cd72

Country Status (2)

Country Link
AU (1) AU2003209753A1 (fr)
WO (1) WO2004067569A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2490280A1 (fr) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Anticorps qui se lient specifiquement a reg iv
EP2322547A1 (fr) 2003-06-25 2011-05-18 Crucell Holland B.V. Lectin specifique de cellules myeloides
WO2010132532A1 (fr) * 2009-05-15 2010-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps réagissant à la surface des lymphocytes b
NO2997944T3 (fr) * 2014-09-19 2018-06-09
WO2019067328A1 (fr) 2017-09-26 2019-04-04 Cero Therapeutics, Inc. Molécules de récepteur d'engloutissement chimérique et méthodes d'utilisation
WO2022036287A1 (fr) * 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Récepteurs chimériques anti-cd72 et utilisations de ceux-ci

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002544174A (ja) * 1999-05-07 2002-12-24 ジェネンテック・インコーポレーテッド Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療

Also Published As

Publication number Publication date
WO2004067569A1 (fr) 2004-08-12
AU2003209753A1 (en) 2004-08-23

Similar Documents

Publication Publication Date Title
WO2005063819A3 (fr) Molecule de liaison humaine contre cd1a
WO2005118644A3 (fr) Molecules de liaison pouvant neutraliser le virus de la rage et utilisation
WO2005012360A3 (fr) Molecules de liaison dirigees contre le coronavirus du syndrome respiratoire aigu severe et applications de celles-ci
WO2004106380A3 (fr) Molecules humaines de liaison a cd3 anti-humain
WO2005014035A3 (fr) Utilisation de galactose oxydase pour la conjugaison chimique selective de molecules d'extraction a des proteines d'interet therapeutique
WO2010077422A3 (fr) Formulations de molécules de liaison d'antigène monodomaines
WO2011020783A3 (fr) Immunoconjugués ciblés
WO2005017205A3 (fr) Cartographie de l'acide nucleique par une analyse lineaire
WO2007141274A3 (fr) Molécules de liaison humaines présentant une activité bactéricide contre les staphylocoques et leurs utilisations
WO2007067730A3 (fr) Anticorps monoclonaux humains contre la proteine tyrosine kinase 7 (ptk7) et procedes pour utiliser des anticorps anti-ptk7
WO2006040129A3 (fr) Conjugues de proteine utilisables en therapie, pour le diagnostic et en chromatographie
WO2006088888A3 (fr) Agents therapeutiques a base d'aptameres utiles dans le traitement de troubles lies au complement
WO2007002223A3 (fr) Anticorps cd19 et utilisations
WO2005079363A3 (fr) Agents therapeutiques a base d'aptameres utiles dans le traitement de troubles lies a un complement
WO2006067122A3 (fr) Molecules de liaison capables de neutraliser le virus du nil occidental et utilisations correspondantes
IL188113A (en) Nucleic acid structures encoded with intersectional responses of psma288–297 and prame425–433, or analogs having their intersecting reaction and their use in the preparation of cancer drugs for nucleic acid structures encoded for psma288–297 and prame425–433 cross-reactors Their intersecting response and their use in the preparation of cancer treatment drugs
MX2008009886A (es) Anticuerpos que enlazan par-2.
WO2007064945A3 (fr) Therapies contre le cancer et compositions pharmaceutiques utilisees dans ces therapies
WO2007067991A3 (fr) Anticorps monoclonaux humains se fixant a l'o8e
WO2006076691A3 (fr) Anticorps 2 associes a la translocation de recepteur immunitaire (irta-2) et leurs utilisations
WO2008036341A3 (fr) Compositions et procédés concernant des anticorps de récepteur du glucagon
WO2008136848A3 (fr) Nouveaux anticorps anti-notch3 et leur utilisation dans la détection et le diagnostic d'une maladie
WO2005097185A3 (fr) Anticorps irta-5 et utilisations de ces derniers
WO2008151819A3 (fr) Traitement de tumeurs à l'aide d'un anticorps anti-l1 spécifique
WO2006029176A3 (fr) Antigenes du cancer du testicule

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 33/2004 ADD "DECLARATION UNDER RULE 4.17: - AS TO APPLICANT S ENTITLEMENT TO APPLY FOR AND BE GRANTED A PATENT (RULE 4.17(II))."; ADD "DECLARATION UNDER RULE 4.17: - OF INVENTORSHIP (RULE 4.17(IV)) FOR US ONLY."

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP